Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version ...

Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means ...

Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its blood cancer drug, Sarclisa (isatuximab) for the treatment of relapsed or ...

Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma On Thursday, Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study ...

TG Therapeutics' stock rose 15% since my November buy recommendation, driven by Briumvi's strong performance and strategic ...

Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV IRAKLIA is the ...

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary ...

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...